Pfizer (PFE) to Release Earnings on Tuesday

Pfizer (NYSE:PFE - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, February 4th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $17.26 billion for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. During the same period last year, the business earned ($0.17) EPS. The business's quarterly revenue was up 31.2% on a year-over-year basis. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Stock Down 1.5 %

PFE traded down $0.41 during trading hours on Friday, hitting $26.51. 37,188,917 shares of the company's stock were exchanged, compared to its average volume of 35,804,484. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer has a 1-year low of $24.48 and a 1-year high of $31.54. The stock's 50-day moving average is $26.25 and its two-hundred day moving average is $27.89. The stock has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.49%. Pfizer's dividend payout ratio is 232.44%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.